Incidence of BK polyomavirus infection after kidney transplantation is independent of type of immunosuppressive therapy

Transpl Infect Dis. 2016 Dec;18(6):850-855. doi: 10.1111/tid.12611. Epub 2016 Nov 30.

Abstract

Background: BK polyomavirus (BKV) infection and BKV nephropathy (BKVN) are risk factors for allograft function and survival.

Methods: We retrospectively analyzed BK viremia and BKVN in 348 patients who received a kidney transplantation donated after brain death (n=232) or living donation (n=116) between 2008 and 2013. A total of 266 patients were treated with standard immunosuppression consisting of basiliximab induction, calcineurin inhibitor (CNI), and mycophenolic acid (MPA, n=219) or everolimus (n=47); 82 patients received more intense immunosuppression with lymphocyte depletion, CNI and MPA (n=38) or everolimus (n=44).

Results: BK viremia occurred in 33 (9.5%) patients in the first year and in 7 (2.0%) recipients in the second year after transplantation. BKVN occurred in 4 (1.1%) patients in the first year. Donor and recipient age, diabetes, previous transplantation, and type of transplantation (donated after brain death vs living donation) were not risk factors (P>.05). BK incidence did not differ depending on induction or maintenance immunosuppression.

Conclusion: Incidence of BK viremia is independent of recipient characteristics, type of transplantation as well as induction and maintenance immunosuppression.

Keywords: BK virus; everolimus; immunosuppression.

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use
  • BK Virus / drug effects*
  • BK Virus / isolation & purification
  • Basiliximab
  • Calcineurin Inhibitors / administration & dosage
  • Calcineurin Inhibitors / adverse effects
  • Calcineurin Inhibitors / therapeutic use
  • Everolimus / administration & dosage
  • Everolimus / adverse effects
  • Everolimus / therapeutic use
  • Female
  • Germany / epidemiology
  • Humans
  • Immunosuppression Therapy / adverse effects*
  • Immunosuppression Therapy / methods
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Incidence
  • Induction Chemotherapy / adverse effects
  • Induction Chemotherapy / methods
  • Kidney Diseases / epidemiology*
  • Kidney Diseases / virology
  • Kidney Transplantation / adverse effects*
  • Maintenance Chemotherapy / adverse effects
  • Maintenance Chemotherapy / methods
  • Male
  • Middle Aged
  • Mycophenolic Acid / administration & dosage
  • Mycophenolic Acid / adverse effects
  • Mycophenolic Acid / therapeutic use
  • Polyomavirus Infections / epidemiology*
  • Polyomavirus Infections / virology
  • Recombinant Fusion Proteins / administration & dosage
  • Recombinant Fusion Proteins / adverse effects
  • Recombinant Fusion Proteins / therapeutic use
  • Retrospective Studies
  • Risk Factors
  • Transplantation, Homologous / adverse effects
  • Tumor Virus Infections / epidemiology*
  • Tumor Virus Infections / virology
  • Viremia / epidemiology*
  • Viremia / virology

Substances

  • Antibodies, Monoclonal
  • Calcineurin Inhibitors
  • Immunosuppressive Agents
  • Recombinant Fusion Proteins
  • Basiliximab
  • Everolimus
  • Mycophenolic Acid